# Ozempic Lawsuit 2026: Update, Claims, Settlement Status

Source: https://www.dietglp.com/blog/ozempic-lawsuit/
Published: 2026-11-13
Keywords: ozempic lawsuit, ozempic lawsuit 2026, ozempic lawsuit update today, ozempic lawsuit blindness, ozempic lawsuit vision loss, ozempic lawsuit stomach paralysis, ozempic lawsuit settlement amounts, ozempic lawsuit side effects, ozempic lawsuit latest news, ozempic class action lawsuit, how to join ozempic lawsuit, is ozempic lawsuit real, what is the ozempic lawsuit about, how many ozempic lawsuits are there, ozempic lawsuits eastern pennsylvania

**TL;DR:** The Ozempic lawsuit is really two groups of federal cases in Philadelphia. As of November 2, 2026, 4,082 cases about stomach and bowel injuries and 278 cases about NAION vision loss were pending against Novo Nordisk and Eli Lilly, who deny the claims. There is no settlement, no payout and no trial date yet, and Ozempic is still FDA approved. If you take a GLP-1, the useful steps are to know the warning signs, keep a simple log, and keep your protein and strength work steady with [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138).

What is the Ozempic lawsuit, and where does it stand in late 2026? **It is two large groups of federal cases in Philadelphia: 4,082 pending cases about stomach and bowel injuries, and 278 about a rare kind of vision loss called NAION.** Those are the official counts from November 2, 2026. The cases name Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda) and Eli Lilly (Trulicity, Mounjaro). Both companies deny the claims. There is no settlement, no payout and no trial date so far.

The topic is back in the news this week. On November 9, 2026, the FDA told every GLP-1 maker to add a NAION warning to its label. We explain that in our [FDA GLP-1 eye warning guide](/blog/fda-glp-1-eye-warning/). This page covers the court side in plain words. It is information, not legal or medical advice.

## Ozempic lawsuit update today: the two case groups

When many people sue over the same product, federal courts can send all the cases to one judge for the early steps. That is called multidistrict litigation, or MDL. Both GLP-1 groups are in front of Judge Karen S. Marston in the Eastern District of Pennsylvania.

| | Stomach and bowel cases | Vision loss cases |
|---|---|---|
| Court name | MDL 3094 | MDL 3163 |
| Created | February 2, 2024 | December 15, 2025 |
| Main injury claimed | Gastroparesis (stomach paralysis) and other gut injuries | NAION, sudden vision loss in one eye |
| Drugs named by the court | Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro | Ozempic, Wegovy, Saxenda, Trulicity |
| Cases pending, Nov 2, 2026 | 4,082 | 278 |
| Cases ever filed | 4,196 | 278 |
| Latest big step | Expert hearing Sept 14 to 18, 2026; closing arguments Oct 13, 2026 | Schedule for early science and warning questions set Aug 27, 2026 |
| Settlement | None | None |

The counts come from the US Judicial Panel on Multidistrict Litigation, which publishes them each month. Law firm websites often show different numbers because they use different dates.

## Ozempic lawsuit stomach paralysis claims: where they stand

This is the older and larger group. People say the drugs caused gastroparesis, a condition where the stomach empties far too slowly, or other gut injuries. They also say the makers knew and did not warn patients and doctors well enough.

Two court steps matter most.

- **August 15, 2025: a test is required.** Judge Marston ruled that a person claiming drug-caused gastroparesis must have had a proper gastric emptying study when they were diagnosed. She also excluded the opinions of the plaintiffs' experts who said a diagnosis from symptoms alone was enough. Gastroparesis claims without that test face a much harder path.
- **September and October 2026: the science hearing.** The judge held a five-day hearing from September 14 to 18, 2026, on what the court calls Cross Cutting Issues 2 and 3. Legal trackers describe these as whether the drugs can cause the injuries at all, and whether the labels warned enough. Closing arguments were on October 13, 2026. When we checked the court's public order list on November 13, 2026, no ruling was posted.

That ruling is the next thing to watch. It could narrow the cases a lot or let them move toward trials.

### What the Ozempic label says about the stomach now

The current Ozempic label (July 2026 version) has a section called Severe Gastrointestinal Adverse Reactions. It was added in October 2025. It says:

- Ozempic is not recommended in people with severe gastroparesis.
- In trials, severe stomach and gut reactions were reported in 0.4% of people on 0.5 mg and 0.8% on 1 mg, versus 0% on placebo.
- After approval, there were reports of ileus (the gut stops moving) and intestinal blockage. The label notes these reports cannot prove cause.

So severe problems are uncommon, but they are on the label. Mild nausea is far more common, and our [guide to managing nausea on Ozempic](/blog/managing-nausea-on-ozempic/) covers that.

## Ozempic lawsuit blindness and vision loss claims

The second group is newer. People say semaglutide or a similar drug caused NAION, a kind of small stroke of the optic nerve that can take away sight in one eye. The federal panel created MDL 3163 on December 15, 2025. It started with about 20 cases. It now has 278.

Key steps so far:

- **June 2, 2026:** a Science Day, where both sides taught the judge the basic medicine.
- **July 2 and August 27, 2026:** orders that set early work on the big shared questions.
- **October 20, 2026:** an order on the fact sheets each plaintiff must fill in.

There are also state court cases. A plaintiffs' lawyer told the Mirror on November 13, 2026, that her firm has filed more than 100 cases in New Jersey state court, with 100 to 150 more waiting. That is the firm's own count.

Novo Nordisk told the Mirror that the lawsuits are "without merit" and that a causal link between semaglutide and NAION has not been established.

### Does the new FDA warning change the lawsuits?

It may matter, but it does not decide them. Many plaintiffs say the US label did not list NAION when they took the drug. The FDA has now required that warning for the whole class. Still, the FDA called it a potential increased risk. In its pooled trial data there were about 6.4 NAION cases per 100,000 person-years on GLP-1 drugs versus 3.8 on comparison treatments. A court still has to decide what the companies knew, when, and whether a drug caused a given person's injury. For the studies, see [Ozempic vision loss (NAION)](/blog/ozempic-vision-loss-naion/) and, for tirzepatide, [Zepbound vision loss](/blog/zepbound-vision-loss/).

## Ozempic lawsuit settlement amounts: is there a payout?

No. As of November 13, 2026:

- No settlement has been announced in either group.
- No jury has heard a case. We found no trial date on the court's public pages.
- There is no claims fund and no form to fill in for a check.

Any "average payout" you see online is a guess from law firm ads. If someone contacts you asking for a fee or your bank details to "release your Ozempic settlement," treat it as a scam. Legal marketing around GLP-1 drugs is heavy right now. Our [Hims FTC lawsuit guide](/blog/hims-ftc-lawsuit/) covers a different case that people often mix up with this one.

## What this means if you take Ozempic now

A lawsuit is a claim. It is not a finding that the drug is unsafe for you. The FDA has not pulled any of these drugs. Here is what is worth doing.

1. **Do not stop or change your dose because of an ad.** Talk to your prescriber first.
2. **Know the red flags.** Call your doctor about severe stomach pain that will not go away, or vomiting that will not stop. Get same-day care for sudden vision loss in one eye.
3. **Tell your doctor your history.** That includes past gastroparesis, gallbladder trouble or optic nerve problems. Our [gallbladder guide](/blog/glp1-and-gallbladder/) explains one of the other label warnings.
4. **Keep a simple log.** Write down your dose dates, what you eat and any symptoms. It helps your doctor spot a pattern early.
5. **Protect your muscle.** When your stomach is touchy, protein is the first thing to drop. Small, protein-first meals are easier to keep down than large ones.

That last step is where [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) fits. It gives you one protein target and one 20-minute workout a day, so the weight you lose is fat and not muscle, even on low-appetite days.

## The bottom line

The Ozempic lawsuit in 2026 is two federal case groups in Philadelphia: 4,082 pending stomach and bowel cases and 278 vision loss cases, plus state cases in New Jersey. A 2025 ruling made gastroparesis claims harder to bring without a stomach emptying test. A ruling on the main science and warning questions is pending after October closing arguments. No one has been paid, and the companies deny the claims. For patients, the labels and your prescriber matter more than the courtroom. Know the warning signs, keep your log, and let [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) handle your daily protein target and workout.

## Sources

- [US Judicial Panel on Multidistrict Litigation: pending MDL dockets by actions pending, November 2, 2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-November-2-2026.pdf)
- [US District Court, Eastern District of Pennsylvania: MDL 3094 (GI injuries) page](https://www.paed.uscourts.gov/mdl/mdl-3094-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-products-liability-litigation-gi)
- [US District Court, Eastern District of Pennsylvania: MDL 3163 (NAION) page](https://www.paed.uscourts.gov/mdl/mdl-3163-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-non-arteritic-anterior-ischemic-optic)
- [JPML transfer order creating MDL 3163, December 15, 2025](https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3163-Transfer_Order-12-25.pdf)
- [Order setting closing arguments on the Rule 702 motions, October 8, 2026](https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/24md3094_sched-ord_6.pdf)
- [Dechert: GLP-1 MDL requires objective testing to proceed (on the August 15, 2025 ruling)](https://www.dechert.com/knowledge/re-torts/2025/9/GLP-1-MDL-Requires-Objective-Testing-to-Proceed.html)
- [Ozempic prescribing information, DailyMed](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ozempic)
- [The Mirror via AOL, November 13, 2026: man sues Ozempic maker over vision loss](https://www.aol.co.uk/articles/grandad-sues-ozempic-maker-novo-112200000.html)


## Frequently asked questions

**Q: What is the Ozempic lawsuit about?**

A: People who took Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro and similar drugs say the makers did not warn them well enough about serious harms. One group of cases is about stomach and bowel injuries such as gastroparesis (stomach paralysis). A second group is about NAION, a rare cause of sudden vision loss. Novo Nordisk and Eli Lilly deny the claims.

**Q: How many Ozempic lawsuits are there?**

A: The federal court panel that tracks these cases counted 4,082 pending cases in the stomach injury group (MDL 3094) and 278 in the vision loss group (MDL 3163) on November 2, 2026. More cases sit in state courts, mainly in New Jersey.

**Q: Is there an Ozempic class action lawsuit?**

A: Not in the US federal cases. They are individual injury lawsuits that are grouped in front of one judge for the early steps. This is called multidistrict litigation, or MDL. Each person still has their own case.

**Q: What are the Ozempic lawsuit settlement amounts?**

A: There are none. No settlement has been announced and no jury has decided a case. Dollar figures you see online are estimates from law firm marketing, not offers from the companies or the court.

**Q: Is the Ozempic lawsuit real or fake?**

A: It is real. The cases are listed on the public website of the US District Court for the Eastern District of Pennsylvania as MDL 3094 and MDL 3163, both in front of Judge Karen S. Marston. A lawsuit is a claim, though. It does not prove the drug caused an injury.

**Q: Is Ozempic being taken off the market?**

A: No. Ozempic is still FDA approved. On November 9, 2026, the FDA required a new NAION warning on all GLP-1 labels, and it did not tell anyone to stop their medicine.

**Q: How do you join the Ozempic lawsuit?**

A: There is no sign-up form with the court and no claims fund. A person files their own case through a licensed lawyer, and deadlines differ by state. We do not recommend law firms and this is not legal advice. Do not stop or change your medicine because of a lawsuit ad. Talk to your prescriber first.

